Failure of the Merck HIV vaccine: an uncertain step forward.

Merlin L Robb

Registry-linked trialAbstract readComment

In one paragraph

Article in Lancet (London, England), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01109342 (Extended Follow-Up for Participants in VRC HIV-1 Recombinant Adenovirus-5 Vector Vaccine Studies in Uganda), which is not on this map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it

0cells of the map it votes in

33citing papers in PubMed, 1 pooled it

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01109342 completednot on this mapstarted 2010, after this paper: background citation

Extended Follow-Up for Participants in VRC HIV-1 Recombinant Adenovirus-5 Vector Vaccine Studies in Uganda

TypeobservationalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2010 to 2012ConditionsHIV Infections

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it.

HIV prevention cost-effectiveness: a systematic review.BMC public health · 2009
Pooled it
A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination.Cell reports. Medicine · 2021
Trial
Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study.AIDS (London, England) · 2011
Trial
Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects.Viruses · 2024
Review
Harnessing Natural Mosaics: Antibody-Instructed, Multi-Envelope HIV-1 Vaccine Design.Viruses · 2021
Article
Vaccine Design Informed by Virus-Induced Immunity.Viral immunology · 2020
Review
Autoimmunity and dysmetabolism of human acquired immunodeficiency syndrome.Immunologic research · 2016
Review
Molecular docking analysis of RN18 and VEC5 in A3G-Vif inhibition.Bioinformation · 2014
Article
Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials.The Journal of infectious diseases · 2012
Article
Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge.Journal of virology · 2012
Article
Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.Journal of virology · 2012
Article
The role of indoleamine 2, 3 dioxygenase in regulating host immunity to leishmania infection.Journal of biomedical science · 2012
Article
Viral Vaccines in India: An Overview.Proceedings of the National Academy of Sciences, India. Section B · 2012
Article
Mosaic HIV-1 Gag antigens can be processed and presented to human HIV-specific CD8+ T cells.Journal of immunology (Baltimore, Md. : 1950) · 2011
Article
Treatment of yellow fever virus with an adenovirus-vectored interferon, DEF201, in a hamster model.Antimicrobial agents and chemotherapy · 2011
Article
The STEP study provides a hint that vaccine induction of the right CD8+ T cell responses can facilitate immune control of HIV.The Journal of infectious diseases · 2011
Article
Variability of bio-clinical parameters in Chinese-origin Rhesus macaques infected with simian immunodeficiency virus: a nonhuman primate AIDS model.PloS one · 2011
Article
Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations.The Journal of general virology · 2011
Article
HIVsirDB: a database of HIV inhibiting siRNAs.PloS one · 2011
Article
The use of cell-delivered gene therapy for the treatment of HIV/AIDS.Immunologic research · 2010
Review

4 · The record

Corrections and comments

Comment on
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.2008

5 · Who and what money

Authors and funding

1 author.

Merlin L RobbUS Military HIV Research Program, Rockville, MD 20850, USA. Electronic address: mrobb@hivresearch.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AIDS VaccinesFemaleHIV InfectionsHumansImmunity, Maternally-AcquiredMaleMulticenter Studies as TopicRandomized Controlled Trials as TopicTreatment FailureAIDS Vaccines

Identifiers

PMID19012958

DOI10.1016/S0140-6736(08)61593-7

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

NCT01109342ClinicalTrials.gov

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.